US3141821A - Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis - Google Patents
Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis Download PDFInfo
- Publication number
- US3141821A US3141821A US799843A US79984359A US3141821A US 3141821 A US3141821 A US 3141821A US 799843 A US799843 A US 799843A US 79984359 A US79984359 A US 79984359A US 3141821 A US3141821 A US 3141821A
- Authority
- US
- United States
- Prior art keywords
- parts
- skin
- composition
- alkyl
- sulphonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003242 anti bacterial agent Substances 0.000 title description 3
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 title description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 title description 2
- 230000003260 anti-sepsis Effects 0.000 title description 2
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 title 1
- 239000011885 synergistic combination Substances 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 17
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 claims description 17
- 229960004068 hexachlorophene Drugs 0.000 claims description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- 231100000252 nontoxic Toxicity 0.000 claims description 9
- 230000003000 nontoxic effect Effects 0.000 claims description 9
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 8
- 230000003385 bacteriostatic effect Effects 0.000 claims description 8
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 claims description 7
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 claims description 5
- 229960002326 bithionol Drugs 0.000 claims description 5
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 claims description 5
- YPNZJHFXFVLXSE-UHFFFAOYSA-N 2-chloro-6-methylphenol Chemical compound CC1=CC=CC(Cl)=C1O YPNZJHFXFVLXSE-UHFFFAOYSA-N 0.000 claims description 4
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 claims description 4
- 229960002447 thiram Drugs 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 3
- 229960001325 triclocarban Drugs 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 241000894006 Bacteria Species 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000191967 Staphylococcus aureus Species 0.000 description 11
- 239000003945 anionic surfactant Substances 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 9
- 229960004106 citric acid Drugs 0.000 description 8
- 208000002874 Acne Vulgaris Diseases 0.000 description 7
- 206010000496 acne Diseases 0.000 description 7
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- -1 hydrocarbon sulphonate Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 4
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 4
- HFQQZARZPUDIFP-UHFFFAOYSA-M sodium;2-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O HFQQZARZPUDIFP-UHFFFAOYSA-M 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- DUMAFWZFOOOEPH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;dodecyl benzenesulfonate Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 DUMAFWZFOOOEPH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000002781 deodorant agent Substances 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical group OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- PULUUPKYWQEYCF-UHFFFAOYSA-N 1,2,3,4-tetrapropylbenzene Chemical compound CCCC1=CC=C(CCC)C(CCC)=C1CCC PULUUPKYWQEYCF-UHFFFAOYSA-N 0.000 description 1
- ZZNDQCACFUJAKJ-UHFFFAOYSA-N 1-phenyltridecan-1-one Chemical compound CCCCCCCCCCCCC(=O)C1=CC=CC=C1 ZZNDQCACFUJAKJ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- AMJCTDBATIKENQ-YRDFTBLNSA-N aureusidin 6-O-beta-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC(O\2)=C1C(=O)C/2=C/C1=CC=C(O)C(O)=C1 AMJCTDBATIKENQ-YRDFTBLNSA-N 0.000 description 1
- AMJCTDBATIKENQ-CMWLGVBASA-N aureusin Natural products OC[C@H]1O[C@@H](Oc2cc(O)c3C(=O)C(=Cc4ccc(O)c(O)c4)Oc3c2)[C@H](O)[C@@H](O)[C@@H]1O AMJCTDBATIKENQ-CMWLGVBASA-N 0.000 description 1
- JMBFLNGHLUPPOF-UHFFFAOYSA-N azane;2-butylnaphthalene-1-sulfonic acid Chemical compound [NH4+].C1=CC=CC2=C(S([O-])(=O)=O)C(CCCC)=CC=C21 JMBFLNGHLUPPOF-UHFFFAOYSA-N 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical class CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- CQHMEFFRIYEJNB-UHFFFAOYSA-N propyl naphthalene-1-sulfonate;sodium Chemical compound [Na].C1=CC=C2C(S(=O)(=O)OCCC)=CC=CC2=C1 CQHMEFFRIYEJNB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940115125 sebulex Drugs 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- KVCGISUBCHHTDD-UHFFFAOYSA-M sodium;4-methylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1 KVCGISUBCHHTDD-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- AMJCTDBATIKENQ-UHFFFAOYSA-N sulphurein Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC(O2)=C1C(=O)C2=CC1=CC=C(O)C(O)=C1 AMJCTDBATIKENQ-UHFFFAOYSA-N 0.000 description 1
- 239000000271 synthetic detergent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/12—Face or body powders for grooming, adorning or absorbing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Definitions
- This invention relates to a bactericidal composition which is especially suitable for application to the human skin, and also, it relates to a method by which pathologic bacteria such as Staphylococcus aureus when present on the skin may be substantially eliminated therefrom.
- Staphylococcus-aureus are transient type bacteria, as against-other-forms-whichnormally reside on the human skin;
- Conventional antiseptics or body cleansers do not-killStaphylocoecus-aureus, but merely serve as growth retarders or as bacteriostats. Understandably, in hospitals or other areas. in which sterile skin conditions are needed, the conventional compositions are ineffective against such pathologic bacteria, and it is necessary to take extraordinary precautions for assurance against possible infection.
- Surgery isone activity in hospitals which requires greatest care against possible infection by the pathologic bacteria, but yet the surgical soaps now. being used are far from being satisfactory in accomplishing this goal.
- an antibacterial agent such as hexachlorophene, tetramethylthiurarndisulfide, 2,2 thiobis (4 chlorophenol), 2,2 thiobis (4 chloro, 6 methylphenol), etc. reduce the number of bacteria on the skin with prolonged use involving days or weeks ofapplication but. are, ineffective as bactericides against Staphylococcus aureus. Further, neither a surfactant alone nor a low pHis effective in killing the Staphylococcus aureus. However, an anionic surfactant and low pH do exhibit bactericidal activity.
- anionic surfactants cannot be used for mypurpose. Those anionic surfactants containing an ester group such as dioctyl ester of sodium sulfosuccinate, sulfated secondary alcohols, sulfated monoglycerides, sulfated lauryl alcohol, etc., are unsatisfactorybecause-of a rapid loss of bactericidal activity upon standing or a rapid develop ment of anundesirable odor, rendering it repugnant for use. Ordinary soap cannot exist as such at the pH required for the present invention.
- an object of this invention is to provide "icea novel composition having an exceptional property for killing Staphylococcus aureus.
- Another object is to provide a composition of' exceptional stability at a low pH and possessing the property of killing Staphylococcus aureus.
- Still another object is to provide a method of killing Staphylococcus aureus on the skin by means of a composition of exceptional stability upon standing for prolonged periods of time.
- compositions comprising a skin substantive bacteriostatic compound and an anionic surface active hydrocarbon sulphonate, at a pH of about 2 to 4.
- the composition can be applied to the skin forthe purpose of killing bacteria, including Staphylococcus aureus, without danger of irritation.
- the composition may be employed as a surgical scrub, a treatment for acne, anunder arm spray deodorant, an after-shave 10- tion or a foot and body powder.
- the skin substantive compound of the formulation of the invention is non-toxic and possesses a bacteriostatic effect on bacteria including Staphylococcus aureus.
- the glass of compounds falling within such a definition are old and well known, thus being understood'by those skilled in the art.
- hexachlorophene, tetramethylthiuramdisulfide, bithionol, trichlorocarbanilide, 2,2 thiobis (4 chlorophenol), 2,2 thiobis (4 chloro, 6 methylphenol), etc. are skin substantive, non-toxic and do exert a bacteriostatic effect on bacteria, but are not bactericidal when used alone.
- the quantity in which these compounds are employed varies in accordance with the use, but generally, about 2 to 15% by weight, based on the quantity of anionic surfactant, may be employed;
- the quantity of bacteriostat may vary outside the above range, in which case less satisfactory results are achieved.
- the anionic surfactant to be used with theskin'substantive bacteriostat may be a sulphonated hydrocarbon, such as an alkane sulphonate or an alkaryl sulphonate in which the aryl nucleus is mono or polynuclear, such as benzene, naphthalene, etc.
- the alkyl substituent on the aryl group may contain from about 1 to 22 carbon atoms. The important consideration is that the com pound be an anionic surfactant. In the alkane sulphonates, the alkyl group contains about 8 to 22 carbon atoms.
- the sulphonic acid group or groups are attached directly to a carbon atom, providing'a stable carbon to sulfur bond, unlike the anionic surfactants mentioned hereinabove as falling outside of the scope of the invention.
- surfactants are sodium propylnaphthalene sulphonate, sodium dodecyl benzene sulphonate, triethanolamine dodecyl benzene sulphonate, sodium-toluene sulfonate, sodium xylene sulphonate, ammonium butyl naphthalene sulphonate, sodium keryl benzene sulphonate, isopropyl amine tetrapropyl benzene sulphonate, sodium dodecane sulphonate, etc.
- the anionic surfactant at the desired pH cooperates orsynergizeswith the skin substantive bacteriostat. to effect. av kill. of bacteria.
- the composition be adjusted to a pH of about 2 to 4 in order to be effective.
- the composition becomes unduly irritating to the skin and thus is preferably avoided; whereas at a higher pH the synergism is adversely influenced to the extent that the composition tends to be ineffective as a bactericide for Staphylococcus aureus.
- the desired pH of the composition is obtained by the use of an acid buffer which is non-toxic and preferably not odoriferous.
- acids having an ionization constant of not more than about 1 10- and as low as about 1x10- and which are non-toxic and lack objectionable odor can be employed for the present invention.
- acids examples include citric acid, phosphoric acid, acetic acid, lactic acid, propionic acid, tartaric acid, hydroxyacetic acid, etc.
- Acids such as sulphuric, hydrochloric, nitric, hydrofluoric, chloroacetic, sulfurous, periodic, picric, etc. are either irritating to the skin or impart bad odor, and so cannot be used.
- the quantity of acid buffer is regulated to maintain a pH of 2-4 when one part of scrub is diluted with five parts of water, otherwise the composition would not be effective against the Staphylococcus aureus bacteria.
- Citric acid monohydrate (19 parts) 2 Triethanolamine (20 parts) Water, q.s. (100 parts) Ethyl alcohol 95% 12 Water, q.s 100 pH, 3.
- Example I Using an in vivo test which parallels actual conditions of use, the pre-surgical scrub of Example I without the hexachlorophene reduced the bacterial population on the hands following a 6 minute scrub by 36%. With the addition of hexachlorophene, providing the composition of Example I, the bacterial count was reduced by 92%.
- the agar used for plating the samples contained a suitable neutralizer, viz, polyoxyethylene sorbitan monooleate to eliminate bacteriostasis.
- the percentage reduction values cited above are relative to a scrub under similar conditions using Ivory soap as zero percent reduction.
- Salicylic acid 0.5 Hexachlorophene 0.1 Ethyl alcohol 95 25.0 Water, q.s 100.0 pH, 3.
- This composition is used in the area of the face to combat the organisms associated with acne vulgaris.
- hexachlorophene is the skin-substantive antibacterial compound.
- the following table shows the synergistic action due to the presence of the hexachlorophene.
- This lotion is used on the face immediately after shaving with no unpleasant smarting or other ill effect.
- the conditions of use of this preparation do not require the presence of salicylic acid for keratolytic effect, but requires more alcohol for faster evaporation from the skin.
- the skin-substantive antibacterial compound is bithionol.
- the dye solutions have been omitted here, to avoid discoloration of clothing, and the alcohol content has been raised.
- the skin-substantive antibacterial compound is 2,2 thiobis (4-chlorophenol).
- EXAMPLE V -BACTERICIDAL FOOT AND BODY POWDER Parts by weight Sodium dodecylbenzenesulfonate (95 active powder) 1.1 Citric acid 0.2 3,4,4 trichlorocarbanilide 1.0 Cornstarch 10.0 Perfume 0.7 Talc 87.0
- the powders are blended together and are then micropulverized.
- the 3,4,4 trichlorocarbanilide is the skin-substantive antibacterial compound. Due to the low solubility of this compound, it cannot be used in clear liquid preparations but is satisfactory for use in powders, detergent bars and opaque lotions.
- tetramethylthiuramdisulfide used here as the skin-substantive antibacterial compound is too insoluble to be used in clear liquid preparations, but is satisfactory for use in powders, detergent bars, and opaque lotions.
- a non-toxic composition comprising a stable anionic surface active sulphonate selected from the group consisting of alkyl sulphonates in which the alkyl group contains approximately 8-22 carbon atoms and alkyl aryl sulphonates in which the alkyl group contains approximately 1-22 carbon atoms and in which the aryl nucleus is selected from the group consisting of benzene and naphthalene, and a non-toxic skin substantive bacteriostatic compound, at a pH of about 2 to 4.
- a method of killing bacteria on the human skin which comprises applying to the skin the composition of claim 1.
- composition of claim 1 wherein the bacteriostatic compound is selected from the group consisting of hexachlorophene, tetramethylthiuramdisulfide, bithionol, trichlorocarbanilide, 2,2 thiobis (4 chlorophenol), and 2,2 thiobis (4 chloro, 6 methylphenol).
- a method of killing bacteria on the human skin which comprises applying to the skin the composition of claim 3.
- a non-toxic composition comprising hexachlorophene and a stable alkaryl sulphonate containing an alkyl substituent of about 1 to 22 carbon atoms and an aryl nucleus selected from the group consisting of benzene and naphthalene, at a pH of about 2 to 4.
- a pre-surgical scrub comprising about 27 parts of triethanolamine dodecylbenzene sulphonate; 4 parts of lauric diethanolamide; 1 part of lanolin; 3 parts of hexachlorophene; about 12 parts of an acid buffer containing 39 parts of phosphoric acid, 19 parts citric acid, 20 parts of triethanola-rnine and 22 parts water; 12 parts ethyl alcohol and 41 parts water.
- An acne composition comprising about 0.7 parts of sodium dodecylbenzene sulphonate, 1.4 parts sodium xylene sulphonate, 0.4 part citric acid, 0.5 part salicylic acid, 0.1 part hexachlorophene, 23 parts ethyl alcohol and 73.9 parts of water.
- An after-shave lotion comprising about 0.7 part of sodium dodecyl benzene sulphonate, about 1.4 parts of sodium eXlene sulphonate, about 0.4 part of citric acid, about 0.1 part of bithionol, about 47.5 parts of ethyl alcohol and about 49.9 parts of water.
- An under-the-arm deodorant comprising about 0.7 part of sodium dodecylbenzene sulphonate, about 1.4 parts of sodium Xylene sulphonate, about 0.4 part of citric acid, about 0.1 part of 2,2 thiobis (4-chlorophenol), about 62 parts of ethyl alcohol and about 35.4 parts of water.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
United States Patent SYNERGESTIC COMBINATIQN 0F ALKYL SUL- FONATES, ALKYLAR-YL SULFONATES AND TOPHIAL ANTIBACTERIAL AGENTS FOR L0- CAL ANTISEPSIS Gerald M. Compeau, Roselle Park, N.J., assignor to Lehn &"Fink Products Corporation, Bloomfield, N.J., a corporation of Delaware No Drawing. Filed Mar.- 17, 1959, Scr. No. 799,843
Claims. ((1161-58) This invention relates to a bactericidal composition which is especially suitable for application to the human skin, and also, it relates to a method by which pathologic bacteria such as Staphylococcus aureus when present on the skin may be substantially eliminated therefrom.
With the widespreaduse of the antibiotic drugs, a serious danger of staphylococcal infection in hospitals and similar institutions has arisen, because many of the drugs retard-growth rather than kill such pathologic bacteria. The Surgeon General ofthe United States has also called attention tothisfact, thusarousing considerable interest in'seekingaworthwhile-solution;
The Staphylococcus-aureusare transient type bacteria, as against-other-forms-whichnormally reside on the human skin; Conventional antiseptics or body cleansers do not-killStaphylocoecus-aureus, but merely serve as growth retarders or as bacteriostats. Understandably, in hospitals or other areas. in which sterile skin conditions are needed, the conventional compositions are ineffective against such pathologic bacteria, and it is necessary to take extraordinary precautions for assurance against possible infection. Surgery isone activity in hospitals which requires greatest care against possible infection by the pathologic bacteria, but yet the surgical soaps now. being used are far from being satisfactory in accomplishing this goal.
Preparations containing as the sole skin substantive component. an antibacterial agent, such as hexachlorophene, tetramethylthiurarndisulfide, 2,2 thiobis (4 chlorophenol), 2,2 thiobis (4 chloro, 6 methylphenol), etc. reduce the number of bacteria on the skin with prolonged use involving days or weeks ofapplication but. are, ineffective as bactericides against Staphylococcus aureus. Further, neither a surfactant alone nor a low pHis effective in killing the Staphylococcus aureus. However, an anionic surfactant and low pH do exhibit bactericidal activity. It appears that on the acid side of the isoelectric point of proteins, and it maybe considered that bacteria are proteinaceous, theproteinbecomescation active or, stated differently, the larger ion of the ionized protein molecule bears a positivecharge. At the-low pH, the cation of the protein and the anionic surfactant combine to form an insoluble precipitate, resulting in suffocation of the bacteria. Unfortunately, however, the kill of bacteria by means of an anionic surfactant at a low pH was not satisfactory; In this connection, my eventual discovery of the synergism between a skin substantive bacteriostatic compound and the anionic surfactant at a low pH was not foreseeable on the basis of previous knowledge of the individual effects of these materials as regards kill of Staphylococcus aureus.
All anionic surfactants cannot be used for mypurpose. Those anionic surfactants containing an ester group such as dioctyl ester of sodium sulfosuccinate, sulfated secondary alcohols, sulfated monoglycerides, sulfated lauryl alcohol, etc., are unsatisfactorybecause-of a rapid loss of bactericidal activity upon standing or a rapid develop ment of anundesirable odor, rendering it repugnant for use. Ordinary soap cannot exist as such at the pH required for the present invention.
Accordingly, an object of this invention is to provide "icea novel composition having an exceptional property for killing Staphylococcus aureus.
Another object is to provide a composition of' exceptional stability at a low pH and possessing the property of killing Staphylococcus aureus.
Still another object is to provide a method of killing Staphylococcus aureus on the skin by means of a composition of exceptional stability upon standing for prolonged periods of time.
Other objects and advantages will become apparent from the following description and explanation thereof.
It is contemplated in accordance with the present invention to provide a composition'comprising a skin substantive bacteriostatic compound and an anionic surface active hydrocarbon sulphonate, at a pH of about 2 to 4. The composition can be applied to the skin forthe purpose of killing bacteria, including Staphylococcus aureus, without danger of irritation. The composition may be employed as a surgical scrub, a treatment for acne, anunder arm spray deodorant, an after-shave 10- tion or a foot and body powder.
The skin substantive compound of the formulation of the invention is non-toxic and possesses a bacteriostatic effect on bacteria including Staphylococcus aureus. The glass of compounds falling within such a definition are old and well known, thus being understood'by those skilled in the art. For example, hexachlorophene, tetramethylthiuramdisulfide, bithionol, trichlorocarbanilide, 2,2 thiobis (4 chlorophenol), 2,2 thiobis (4 chloro, 6 methylphenol), etc. are skin substantive, non-toxic and do exert a bacteriostatic effect on bacteria, but are not bactericidal when used alone. The quantity in which these compounds are employed varies in accordance with the use, but generally, about 2 to 15% by weight, based on the quantity of anionic surfactant, may be employed; The quantity of bacteriostat may vary outside the above range, in which case less satisfactory results are achieved.
The anionic surfactant to be used with theskin'substantive bacteriostat may be a sulphonated hydrocarbon, such as an alkane sulphonate or an alkaryl sulphonate in which the aryl nucleus is mono or polynuclear, such as benzene, naphthalene, etc. The alkyl substituent on the aryl group may contain from about 1 to 22 carbon atoms. The important consideration is that the com pound be an anionic surfactant. In the alkane sulphonates, the alkyl group contains about 8 to 22 carbon atoms. The sulphonic acid group or groups are attached directly to a carbon atom, providing'a stable carbon to sulfur bond, unlike the anionic surfactants mentioned hereinabove as falling outside of the scope of the invention. There may be one or more sulphonic acid groups in the molecule and the group may be a free acid group or combined with such radicals as ammonium; alkali metal, e.g., sodium, potassium, etc.; substituted ammonia such as the amines; etc. Specific examples of such surfactants are sodium propylnaphthalene sulphonate, sodium dodecyl benzene sulphonate, triethanolamine dodecyl benzene sulphonate, sodium-toluene sulfonate, sodium xylene sulphonate, ammonium butyl naphthalene sulphonate, sodium keryl benzene sulphonate, isopropyl amine tetrapropyl benzene sulphonate, sodium dodecane sulphonate, etc. The anionic surfactant at the desired pH cooperates orsynergizeswith the skin substantive bacteriostat. to effect. av kill. of bacteria. including Staphylococcus. aureusin excess. of what might be predicted on the basis of their individual effects. The synergism exists as long as the two compounds are together in any relative proportions, but the cooperation is particularly effective when the bacteriostat is present in an amount of about 5 to 10% by weight, based on the surfactant.
It is also important that the composition be adjusted to a pH of about 2 to 4 in order to be effective. At a lower pH than the range mentioned, the composition becomes unduly irritating to the skin and thus is preferably avoided; whereas at a higher pH the synergism is adversely influenced to the extent that the composition tends to be ineffective as a bactericide for Staphylococcus aureus. For our purpose, the desired pH of the composition is obtained by the use of an acid buffer which is non-toxic and preferably not odoriferous. Generally, acids having an ionization constant of not more than about 1 10- and as low as about 1x10- and which are non-toxic and lack objectionable odor can be employed for the present invention. Examples of the acids are citric acid, phosphoric acid, acetic acid, lactic acid, propionic acid, tartaric acid, hydroxyacetic acid, etc. Acids such as sulphuric, hydrochloric, nitric, hydrofluoric, chloroacetic, sulfurous, periodic, picric, etc. are either irritating to the skin or impart bad odor, and so cannot be used. For some applications, such as a pre-surgical scrub, the quantity of acid buffer is regulated to maintain a pH of 2-4 when one part of scrub is diluted with five parts of water, otherwise the composition would not be effective against the Staphylococcus aureus bacteria.
To provide a fuller understanding of the present invention, reference will be had to the specific examples.
EXAMPLE I.PRE-SURGICAL SCRUB Parts by weight Triethanolamine dodecylbenzene sulphonate (60% active) 45 Laurie diethanolamide (foam stabilizer) 4 Liquid lanolin (emollient) 1 Hexachlorophene 3 Buffer:
Phosphoric acid 85% (46 parts)] Citric acid monohydrate (19 parts) 2 Triethanolamine (20 parts) Water, q.s. (100 parts) Ethyl alcohol 95% 12 Water, q.s 100 pH, 3.
Using an in vivo test which parallels actual conditions of use, the pre-surgical scrub of Example I without the hexachlorophene reduced the bacterial population on the hands following a 6 minute scrub by 36%. With the addition of hexachlorophene, providing the composition of Example I, the bacterial count was reduced by 92%. In determining the counts, the agar used for plating the samples contained a suitable neutralizer, viz, polyoxyethylene sorbitan monooleate to eliminate bacteriostasis. The percentage reduction values cited above are relative to a scrub under similar conditions using Ivory soap as zero percent reduction.
The effectiveness of hexachlorophene alone, also known as G-11, as a bactericide has been tested by prior Workers. This compound has been evaluated in the form of bar soap, liquid soap or pHisoderm, and found to be a bacteriostat and not to have any more effect than Ivory soap against bacteria. This work is reported in Drug Standards, vol. 19, Nos. 9 and 10, page 170 (1951).
Additional examples are given below.
EXAMPLE II.ACNE PREPARATION Parts by weight Sodium dodecylbenzenesulfonate (50% active)--- 1.4 Sodium xylenesulfonate (40% active) 3.6 Citric acid 0.4
Salicylic acid 0.5 Hexachlorophene 0.1 Ethyl alcohol 95 25.0 Water, q.s 100.0 pH, 3.
This composition is used in the area of the face to combat the organisms associated with acne vulgaris. The
' Sodium xylenesulfonate (40% active) salicyclic acid provides a moderate keratolytic effect, and hexachlorophene is the skin-substantive antibacterial compound. Under standardized conditions of testing (sterile swab sampling) on the faces of test human subjects, the following table shows the synergistic action due to the presence of the hexachlorophene.
Table l Bacteria per square Facial treatment-10 minutes: inch of face Control (water) 34,025 Acne preparationno hexachlorophene 5,500 Acne preparation-0.1% hexachlorophene 52 Suitable neutralizers such as 10% horse serum or polyoxyethylene sorbitan monooleate were used in subculturing the facial swabs to eliminate bacteriostasis. Consulting dermatologists report excellent results are obtained with this preparation in treating their acne patients.
This lotion is used on the face immediately after shaving with no unpleasant smarting or other ill effect. The conditions of use of this preparation do not require the presence of salicylic acid for keratolytic effect, but requires more alcohol for faster evaporation from the skin. The skin-substantive antibacterial compound is bithionol.
EXAMPLE IV.BACTERICIDAL UNDER-ARM SPRAY DEODORANT Parts by weight Sodium dodecylbenzenesulfonate (50% active)--- 1.4 3.6 0.4 0.1
Citric acid 2,2 thiobis (4-chlorophenol) Perfume 0.3 Ethyl alcohol 65.0 Water, q.s 100.0 pH, 3.
The dye solutions have been omitted here, to avoid discoloration of clothing, and the alcohol content has been raised. The skin-substantive antibacterial compound is 2,2 thiobis (4-chlorophenol).
EXAMPLE V.-BACTERICIDAL FOOT AND BODY POWDER Parts by weight Sodium dodecylbenzenesulfonate (95 active powder) 1.1 Citric acid 0.2 3,4,4 trichlorocarbanilide 1.0 Cornstarch 10.0 Perfume 0.7 Talc 87.0
pH (in aqueous extract), 3.
The powders are blended together and are then micropulverized. Here the 3,4,4 trichlorocarbanilide is the skin-substantive antibacterial compound. Due to the low solubility of this compound, it cannot be used in clear liquid preparations but is satisfactory for use in powders, detergent bars and opaque lotions.
E! J EXAMPLE VI.BACTERICIDAL SYNTHETIC DETERGENT BAR Parts by weight Sodium dodecylbenzenesulfonate (95% active powpH (in Water), 3.
These materials are compounded in a suitable mixer and are then extruded in bar form. The tetramethylthiuramdisulfide used here as the skin-substantive antibacterial compound is too insoluble to be used in clear liquid preparations, but is satisfactory for use in powders, detergent bars, and opaque lotions.
Having thus provided a description of my invention along with specific examples, the scope thereof is defined by the appended claims.
I claim:
1. A non-toxic composition comprising a stable anionic surface active sulphonate selected from the group consisting of alkyl sulphonates in which the alkyl group contains approximately 8-22 carbon atoms and alkyl aryl sulphonates in which the alkyl group contains approximately 1-22 carbon atoms and in which the aryl nucleus is selected from the group consisting of benzene and naphthalene, and a non-toxic skin substantive bacteriostatic compound, at a pH of about 2 to 4.
2. A method of killing bacteria on the human skin which comprises applying to the skin the composition of claim 1.
3. The composition of claim 1 wherein the bacteriostatic compound is selected from the group consisting of hexachlorophene, tetramethylthiuramdisulfide, bithionol, trichlorocarbanilide, 2,2 thiobis (4 chlorophenol), and 2,2 thiobis (4 chloro, 6 methylphenol).
4. A method of killing bacteria on the human skin which comprises applying to the skin the composition of claim 3.
5. A non-toxic composition comprising hexachlorophene and a stable alkaryl sulphonate containing an alkyl substituent of about 1 to 22 carbon atoms and an aryl nucleus selected from the group consisting of benzene and naphthalene, at a pH of about 2 to 4.
6. A method of killing bacteria on the human skin which comprises applying to the skin the composition of claim 5.
7. A pre-surgical scrub comprising about 27 parts of triethanolamine dodecylbenzene sulphonate; 4 parts of lauric diethanolamide; 1 part of lanolin; 3 parts of hexachlorophene; about 12 parts of an acid buffer containing 39 parts of phosphoric acid, 19 parts citric acid, 20 parts of triethanola-rnine and 22 parts water; 12 parts ethyl alcohol and 41 parts water.
8. An acne composition comprising about 0.7 parts of sodium dodecylbenzene sulphonate, 1.4 parts sodium xylene sulphonate, 0.4 part citric acid, 0.5 part salicylic acid, 0.1 part hexachlorophene, 23 parts ethyl alcohol and 73.9 parts of water.
9. An after-shave lotion comprising about 0.7 part of sodium dodecyl benzene sulphonate, about 1.4 parts of sodium eXlene sulphonate, about 0.4 part of citric acid, about 0.1 part of bithionol, about 47.5 parts of ethyl alcohol and about 49.9 parts of water.
10. An under-the-arm deodorant comprising about 0.7 part of sodium dodecylbenzene sulphonate, about 1.4 parts of sodium Xylene sulphonate, about 0.4 part of citric acid, about 0.1 part of 2,2 thiobis (4-chlorophenol), about 62 parts of ethyl alcohol and about 35.4 parts of water.
References Cited in the file of this patent UNITED STATES PATENTS 2,634,240 Showalter et al Apr. 7, 1953 2,746,928 Darragh May 22, 1956 2,846,398 Beaver et a1. Aug. 5, 1958 2,898,264 Weber Aug. 4, 1959 2,937,147 Goldwasser May 17, 1960 FOREIGN PATENTS 1,088,387 France Sept. 8, 1954 786,285 Great Britain Nov. 13, 1957 OTHER REFERENCES Wadley: The Evidence Required To Show Synergistic Action of Insecticides and a Short Cut in Analysis, Et-223, June 1945, 7 p. brochure.
Flett et al.: Am. Perfumer and Ess. Oil Review, 48: 12, December 1946, pages 63-4, 69.
Freeman: Surgery, vol. 25, June 1949, pp. 897-901, 167-901.
Harry: Cosmetic Materials, 1st Ed., Leonard Hill Ltd., London (1950), pp. 23-4, 166-8, 272-3 and 312-3.
Shay: Chem. Absts., vol. 45, 1951, p. 7747.
Chemical Abstracts, vol. 47:9562c (1953) (abstract of Masuyama, Japan J. Bacteriol. 5, 263-6 (1950)).
Schwarz et al.: Surface Active Agents and Detergents, vol. H, Interscience PubL, NY. (1958), pp. 231-3 and 320-1.
Sebulex, Reg. Trademark File No. 676,451, March 31, 1959. (First use in commerce April 15, 1958.)
Fein, H. D.: Modern Drug Encyclopedia and Therepeutic Index, 1958, 7th Edition, N.Y., Donnelley Corp, 1958, page 477.
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No; 3 l41 821 July 21 1964 Gerald Mo Compeau s in the above numbered pat- It is hereby certified that error appear tters Patent should read as en'b requiring correction and that the said Le corrected below Column 6,, line 11 for "exlene" read xylene line 41.1 strike out; "'167-90l" Signed and sealed this 17th day of November 1964.,
(SEAL) Attest:
EDWARD J. BRENNER ERNEST W. SWIDER' Attesting Officer Commissioner of Patents
Claims (2)
1. A NON-TOXIC COMPOSITION COMPRISING A STABLE ANIONIC SURFACE ACTIVE SULPHONATE SELECTED FROM THE GROUP CONSISTING OF ALKYL SULPHONATES IN WHICH THE ALKYL GROUP CONTAINS APPROXIMATELY 8-22 CARBON ATOMS AND ALKYL ARYL SULPHONATES IN WHICH THE ALKYL GROUP CONTAINS APPROXIMATELY 1-22 CARBON ATOMS AND IN WHICH THE ARYL NUCLEUS IS SELECTED FROM THE GROUP CONSISTING OF BENZENE AND NAPHTHALENE, AND A NON-TOXIC SKIN SUBSTANTIVE BACTERIOSTATIC COMPOUND, AT A PH OF ABOUT 2 TO 4.
3. THE COMPOSITION OF CLAIM 1 WHEREIN THE BACTERIOSTATIC COMPOUND IS SELECTED FROM THE GROUP CONSISTING OF HEXACHLOROPHENE, TETRAMETHYLTHIURAMDISULFIDE, BITHIONOL, TRICHLOROCARBANILIDE, 2,2'' THIOBIS (4 CHLOROPHENOL), AND 2,2'' THIOBIS (4 CHLORO,6 METHYLPHENOL).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US799843A US3141821A (en) | 1959-03-17 | 1959-03-17 | Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US799843A US3141821A (en) | 1959-03-17 | 1959-03-17 | Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3141821A true US3141821A (en) | 1964-07-21 |
Family
ID=25176906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US799843A Expired - Lifetime US3141821A (en) | 1959-03-17 | 1959-03-17 | Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3141821A (en) |
Cited By (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257450A (en) * | 1963-02-28 | 1966-06-21 | Guardian Chemical Corp | Organic hypochlorous acid derivatives and a process for their manufacture |
| US3281365A (en) * | 1963-12-23 | 1966-10-25 | Monsanto Co | Antiseptic detergent compositions |
| FR2099687A1 (en) * | 1970-07-30 | 1972-03-17 | Procter & Gamble | |
| US3903259A (en) * | 1971-01-07 | 1975-09-02 | Una L Hart | Method of deodorizing diapers and human excreta |
| DE2647952A1 (en) * | 1975-10-24 | 1977-05-05 | Chapman Chem Co | ANTIMICROBIAL COMPOSITION AND CONCENTRATE AND METHOD OF MANUFACTURING IT |
| US4089942A (en) * | 1976-01-29 | 1978-05-16 | L'oreal | Deodorant composition and process |
| US4258056A (en) * | 1978-12-18 | 1981-03-24 | Economics Laboratory, Inc. | Control of mastitis and compositions therefor |
| WO1981001516A1 (en) * | 1979-12-03 | 1981-06-11 | Economics Lab | Control of mastitis and compositions therefor |
| DE3227126A1 (en) * | 1981-07-20 | 1983-02-03 | Kimberly-Clark Corp., 54956 Neenah, Wis. | VIRUS KILLING PROCEDURE, COMPOSITION AND PRODUCT |
| DE3229097A1 (en) * | 1982-08-04 | 1984-02-09 | Schülke & Mayr GmbH, 2000 Hamburg | Microbicidal agents |
| US4602011A (en) * | 1975-10-24 | 1986-07-22 | Chapman Chemical Company | Antimicrobial compositions and methods of using same |
| US4614612A (en) * | 1977-12-22 | 1986-09-30 | Lever Brothers Company | Liquid detergent composition |
| US4766113A (en) * | 1975-10-24 | 1988-08-23 | Chapman Chemical Company | Antimicrobial compositions and methods of using same |
| US4828912A (en) * | 1981-07-20 | 1989-05-09 | Kimberly-Clark Corporation | Virucidal product having virucidal and/or germicidal properties |
| US4923523A (en) * | 1986-12-13 | 1990-05-08 | Henkel Kommanditgesellschaft Auf Aktien | Short-chain alkane sulfonic acids in cleaning preparations and disinfectants |
| US4945110A (en) * | 1987-06-15 | 1990-07-31 | Quali Tech, Inc. | Membrame-forming veterinary antibacterial teat dip |
| WO1998044791A1 (en) * | 1997-04-04 | 1998-10-15 | The Clorox Company | Antimicrobial cleaning composition |
| WO1998055093A1 (en) * | 1997-06-04 | 1998-12-10 | The Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions |
| US5968539A (en) * | 1997-06-04 | 1999-10-19 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria |
| US6183757B1 (en) | 1997-06-04 | 2001-02-06 | Procter & Gamble Company | Mild, rinse-off antimicrobial cleansing compositions which provide improved immediate germ reduction during washing |
| US6183763B1 (en) | 1997-06-04 | 2001-02-06 | Procter & Gamble Company | Antimicrobial wipes which provide improved immediate germ reduction |
| US6190675B1 (en) | 1997-06-04 | 2001-02-20 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide improved residual benefit versus gram positive bacteria |
| US6190674B1 (en) | 1997-06-04 | 2001-02-20 | Procter & Gamble Company | Liquid antimicrobial cleansing compositions |
| US6197315B1 (en) | 1997-06-04 | 2001-03-06 | Procter & Gamble Company | Antimicrobial wipes which provide improved residual benefit versus gram negative bacteria |
| US6210695B1 (en) | 1997-06-04 | 2001-04-03 | The Procter & Gamble Company | Leave-on antimicrobial compositions |
| US6214363B1 (en) | 1997-11-12 | 2001-04-10 | The Procter & Gamble Company | Liquid antimicrobial cleansing compositions which provide residual benefit versus gram negative bacteria |
| US6284259B1 (en) | 1997-11-12 | 2001-09-04 | The Procter & Gamble Company | Antimicrobial wipes which provide improved residual benefit versus Gram positive bacteria |
| US6287583B1 (en) | 1997-11-12 | 2001-09-11 | The Procter & Gamble Company | Low-pH, acid-containing personal care compositions which exhibit reduced sting |
| US6287577B1 (en) | 1997-11-12 | 2001-09-11 | The Procter & Gamble Company | Leave-on antimicrobial compositions which provide improved residual benefit versus gram positive bacteria |
| US6294186B1 (en) | 1997-06-04 | 2001-09-25 | Peter William Beerse | Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
| US6379685B1 (en) * | 1997-09-26 | 2002-04-30 | Ecolab Inc. | Acidic aqueous chlorite teat dip with improved emollient providing shelf life, sanitizing capacity and tissue protection |
| US6436885B2 (en) | 2000-01-20 | 2002-08-20 | The Procter & Gamble Company | Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid |
| US6551608B2 (en) | 2000-03-06 | 2003-04-22 | Porex Technologies Corporation | Porous plastic media with antiviral or antimicrobial properties and processes for making the same |
| US20030235550A1 (en) * | 2002-06-21 | 2003-12-25 | Pan Robert Ya-Lin | Antimicrobial compositions, products and methods employing same |
| US6749869B1 (en) | 1997-09-26 | 2004-06-15 | Ecolab | Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection |
| US6812196B2 (en) | 2000-06-05 | 2004-11-02 | S.C. Johnson & Son, Inc. | Biocidal cleaner composition containing acid-anionic surfactant-alcohol combinations and method of using the composition |
| US20050100612A1 (en) * | 2003-11-07 | 2005-05-12 | Viratox, L.L.C. | Virucidal activities of cetylpyridinium chloride |
| US20050260243A1 (en) * | 2004-04-26 | 2005-11-24 | The Procter & Gamble Company | Method of treating microbial plant diseases |
| US20070020384A1 (en) * | 1998-09-23 | 2007-01-25 | Alberte Randall S | Environmentally benign crop protection agents |
| US20090047364A1 (en) * | 2007-05-18 | 2009-02-19 | Crudden Joseph J | Disinfecting methods and compositions |
| WO2009090178A1 (en) * | 2008-01-16 | 2009-07-23 | Glaxo Group Limited | Novel formulation |
| US7569530B1 (en) | 2003-06-20 | 2009-08-04 | The Procter & Gamble Company | Antimicrobial compositions, products and methods employing same |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US20100144877A1 (en) * | 2007-02-21 | 2010-06-10 | Viratox, L.L.C. | Synergistic Enhancement of Calcium Propionate |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US20110045037A1 (en) * | 2007-11-30 | 2011-02-24 | Foamix Ltd. | Foam containing benzoyl peroxide |
| US20110178162A1 (en) * | 2005-10-14 | 2011-07-21 | Medical University Of South Carolina | Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
| US8486376B2 (en) * | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
| US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
| US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
| RU2610172C2 (en) * | 2011-05-27 | 2017-02-08 | Галдерма С.А. | Composition for face washing |
| US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US10610594B2 (en) | 2012-11-13 | 2020-04-07 | Galderma S.A. | BPO wash gel composition |
| US11446272B2 (en) | 2012-11-13 | 2022-09-20 | Galderma Holding SA | BPO wash emulsion composition |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2634240A (en) * | 1949-07-09 | 1953-04-07 | Standard Oil Dev Co | Alkyl aryl sulfonate detergent composition |
| FR1088387A (en) * | 1952-09-06 | 1955-03-07 | Unilever Nv | Improvements to detergent compositions |
| US2746928A (en) * | 1952-06-26 | 1956-05-22 | California Research Corp | Germicidal detergent compositions |
| GB786285A (en) * | 1955-01-26 | 1957-11-13 | Monsanto Chemicals | Improvements in detergents and other compositions |
| US2846398A (en) * | 1955-12-27 | 1958-08-05 | Monsanto Chemicals | Antiseptic detergent composition |
| US2898264A (en) * | 1955-09-15 | 1959-08-04 | Colgate Palmolive Co | Bactericidal compositions to be used specially for food-industries equipment |
| US2937147A (en) * | 1955-09-28 | 1960-05-17 | Lever Brothers Ltd | Stabilized germicidal soaps and process of making the same |
-
1959
- 1959-03-17 US US799843A patent/US3141821A/en not_active Expired - Lifetime
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2634240A (en) * | 1949-07-09 | 1953-04-07 | Standard Oil Dev Co | Alkyl aryl sulfonate detergent composition |
| US2746928A (en) * | 1952-06-26 | 1956-05-22 | California Research Corp | Germicidal detergent compositions |
| FR1088387A (en) * | 1952-09-06 | 1955-03-07 | Unilever Nv | Improvements to detergent compositions |
| GB786285A (en) * | 1955-01-26 | 1957-11-13 | Monsanto Chemicals | Improvements in detergents and other compositions |
| US2898264A (en) * | 1955-09-15 | 1959-08-04 | Colgate Palmolive Co | Bactericidal compositions to be used specially for food-industries equipment |
| US2937147A (en) * | 1955-09-28 | 1960-05-17 | Lever Brothers Ltd | Stabilized germicidal soaps and process of making the same |
| US2846398A (en) * | 1955-12-27 | 1958-08-05 | Monsanto Chemicals | Antiseptic detergent composition |
Cited By (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3257450A (en) * | 1963-02-28 | 1966-06-21 | Guardian Chemical Corp | Organic hypochlorous acid derivatives and a process for their manufacture |
| US3281365A (en) * | 1963-12-23 | 1966-10-25 | Monsanto Co | Antiseptic detergent compositions |
| FR2099687A1 (en) * | 1970-07-30 | 1972-03-17 | Procter & Gamble | |
| US3903259A (en) * | 1971-01-07 | 1975-09-02 | Una L Hart | Method of deodorizing diapers and human excreta |
| US4602011A (en) * | 1975-10-24 | 1986-07-22 | Chapman Chemical Company | Antimicrobial compositions and methods of using same |
| DE2647952A1 (en) * | 1975-10-24 | 1977-05-05 | Chapman Chem Co | ANTIMICROBIAL COMPOSITION AND CONCENTRATE AND METHOD OF MANUFACTURING IT |
| US4766113A (en) * | 1975-10-24 | 1988-08-23 | Chapman Chemical Company | Antimicrobial compositions and methods of using same |
| US4089942A (en) * | 1976-01-29 | 1978-05-16 | L'oreal | Deodorant composition and process |
| US4614612A (en) * | 1977-12-22 | 1986-09-30 | Lever Brothers Company | Liquid detergent composition |
| US4258056A (en) * | 1978-12-18 | 1981-03-24 | Economics Laboratory, Inc. | Control of mastitis and compositions therefor |
| US4376787A (en) * | 1979-12-03 | 1983-03-15 | Economics Laboratory, Inc. | Control of mastitis |
| WO1981001516A1 (en) * | 1979-12-03 | 1981-06-11 | Economics Lab | Control of mastitis and compositions therefor |
| DE3227126A1 (en) * | 1981-07-20 | 1983-02-03 | Kimberly-Clark Corp., 54956 Neenah, Wis. | VIRUS KILLING PROCEDURE, COMPOSITION AND PRODUCT |
| US4828912A (en) * | 1981-07-20 | 1989-05-09 | Kimberly-Clark Corporation | Virucidal product having virucidal and/or germicidal properties |
| DE3229097A1 (en) * | 1982-08-04 | 1984-02-09 | Schülke & Mayr GmbH, 2000 Hamburg | Microbicidal agents |
| US4923523A (en) * | 1986-12-13 | 1990-05-08 | Henkel Kommanditgesellschaft Auf Aktien | Short-chain alkane sulfonic acids in cleaning preparations and disinfectants |
| US4945110A (en) * | 1987-06-15 | 1990-07-31 | Quali Tech, Inc. | Membrame-forming veterinary antibacterial teat dip |
| AU741374B2 (en) * | 1997-04-04 | 2001-11-29 | Clorox Company, The | Antimicrobial cleaning composition |
| WO1998044791A1 (en) * | 1997-04-04 | 1998-10-15 | The Clorox Company | Antimicrobial cleaning composition |
| US6190675B1 (en) | 1997-06-04 | 2001-02-20 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide improved residual benefit versus gram positive bacteria |
| US6294186B1 (en) | 1997-06-04 | 2001-09-25 | Peter William Beerse | Antimicrobial compositions comprising a benzoic acid analog and a metal salt |
| US6183763B1 (en) | 1997-06-04 | 2001-02-06 | Procter & Gamble Company | Antimicrobial wipes which provide improved immediate germ reduction |
| WO1998055093A1 (en) * | 1997-06-04 | 1998-12-10 | The Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions |
| US6190674B1 (en) | 1997-06-04 | 2001-02-20 | Procter & Gamble Company | Liquid antimicrobial cleansing compositions |
| US6197315B1 (en) | 1997-06-04 | 2001-03-06 | Procter & Gamble Company | Antimicrobial wipes which provide improved residual benefit versus gram negative bacteria |
| US6210695B1 (en) | 1997-06-04 | 2001-04-03 | The Procter & Gamble Company | Leave-on antimicrobial compositions |
| US6183757B1 (en) | 1997-06-04 | 2001-02-06 | Procter & Gamble Company | Mild, rinse-off antimicrobial cleansing compositions which provide improved immediate germ reduction during washing |
| US5968539A (en) * | 1997-06-04 | 1999-10-19 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria |
| US6699510B2 (en) | 1997-09-26 | 2004-03-02 | Ecolab Inc. | Acidic aqueous chlorite teat dip with improved visual indicator stability, extended shelf life, sanitizing capacity and tissue protection |
| US6379685B1 (en) * | 1997-09-26 | 2002-04-30 | Ecolab Inc. | Acidic aqueous chlorite teat dip with improved emollient providing shelf life, sanitizing capacity and tissue protection |
| US6436444B1 (en) | 1997-09-26 | 2002-08-20 | Ecolab Inc. | Acidic aqueous chlorite teat dip providing shelf life sanitizing capacity and tissue protection |
| USRE41279E1 (en) | 1997-09-26 | 2010-04-27 | Ecolab Inc. | Acidic aqueous chlorite teat dip with improved visual indicator stability, extended shelf life, sanitizing capacity and tissue protection |
| US6749869B1 (en) | 1997-09-26 | 2004-06-15 | Ecolab | Acidic aqueous chlorite teat dip providing shelf life, sanitizing capacity and tissue protection |
| US6287577B1 (en) | 1997-11-12 | 2001-09-11 | The Procter & Gamble Company | Leave-on antimicrobial compositions which provide improved residual benefit versus gram positive bacteria |
| US6287583B1 (en) | 1997-11-12 | 2001-09-11 | The Procter & Gamble Company | Low-pH, acid-containing personal care compositions which exhibit reduced sting |
| US6284259B1 (en) | 1997-11-12 | 2001-09-04 | The Procter & Gamble Company | Antimicrobial wipes which provide improved residual benefit versus Gram positive bacteria |
| US6214363B1 (en) | 1997-11-12 | 2001-04-10 | The Procter & Gamble Company | Liquid antimicrobial cleansing compositions which provide residual benefit versus gram negative bacteria |
| US20070020384A1 (en) * | 1998-09-23 | 2007-01-25 | Alberte Randall S | Environmentally benign crop protection agents |
| US6436885B2 (en) | 2000-01-20 | 2002-08-20 | The Procter & Gamble Company | Antimicrobial cleansing compositions containing 2-pyrrolidone-5-carboxylic acid |
| US6551608B2 (en) | 2000-03-06 | 2003-04-22 | Porex Technologies Corporation | Porous plastic media with antiviral or antimicrobial properties and processes for making the same |
| US6812196B2 (en) | 2000-06-05 | 2004-11-02 | S.C. Johnson & Son, Inc. | Biocidal cleaner composition containing acid-anionic surfactant-alcohol combinations and method of using the composition |
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| US20090202463A1 (en) * | 2002-06-21 | 2009-08-13 | The Procter & Gamble Company Attn: Chief Patent Counsel | Antimicrobial compositions, products and methods employing same |
| US20040001797A1 (en) * | 2002-06-21 | 2004-01-01 | Abel Saud | Antimicrobial compositions, products and methods employing same |
| US20030235550A1 (en) * | 2002-06-21 | 2003-12-25 | Pan Robert Ya-Lin | Antimicrobial compositions, products and methods employing same |
| US8435498B2 (en) | 2002-10-25 | 2013-05-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US8840869B2 (en) | 2002-10-25 | 2014-09-23 | Foamix Ltd. | Body cavity foams |
| US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US8741265B2 (en) | 2002-10-25 | 2014-06-03 | Foamix Ltd. | Penetrating pharmaceutical foam |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US8722021B2 (en) | 2002-10-25 | 2014-05-13 | Foamix Ltd. | Foamable carriers |
| US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
| US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
| US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
| US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
| US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US8486376B2 (en) * | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US8119106B2 (en) | 2003-04-28 | 2012-02-21 | Foamix Ltd | Foamable iodine compositions |
| US8486375B2 (en) | 2003-04-28 | 2013-07-16 | Foamix Ltd. | Foamable compositions |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US20090215854A1 (en) * | 2003-06-20 | 2009-08-27 | The Procter & Gamble Company | Antimicrobial compositions, products and methods employing same |
| US7569530B1 (en) | 2003-06-20 | 2009-08-04 | The Procter & Gamble Company | Antimicrobial compositions, products and methods employing same |
| US8703105B2 (en) | 2003-08-04 | 2014-04-22 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8114385B2 (en) | 2003-08-04 | 2012-02-14 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US9050253B2 (en) | 2003-08-04 | 2015-06-09 | Foamix Pharmaceuticals Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US9101662B2 (en) | 2003-08-04 | 2015-08-11 | Foamix Pharmaceuticals Ltd. | Compositions with modulating agents |
| US8362091B2 (en) | 2003-08-04 | 2013-01-29 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8518378B2 (en) | 2003-08-04 | 2013-08-27 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US20050100612A1 (en) * | 2003-11-07 | 2005-05-12 | Viratox, L.L.C. | Virucidal activities of cetylpyridinium chloride |
| US20050260243A1 (en) * | 2004-04-26 | 2005-11-24 | The Procter & Gamble Company | Method of treating microbial plant diseases |
| US20110178162A1 (en) * | 2005-10-14 | 2011-07-21 | Medical University Of South Carolina | Targeting pax2 for the induction of defb1-mediated tumor immunity and cancer therapy |
| US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US8795635B2 (en) | 2006-11-14 | 2014-08-05 | Foamix Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US20100144877A1 (en) * | 2007-02-21 | 2010-06-10 | Viratox, L.L.C. | Synergistic Enhancement of Calcium Propionate |
| US8741954B2 (en) | 2007-02-21 | 2014-06-03 | Viratox, L.L.C. | Synergistic enhancement of calcium propionate |
| US20090047364A1 (en) * | 2007-05-18 | 2009-02-19 | Crudden Joseph J | Disinfecting methods and compositions |
| US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| US20110045037A1 (en) * | 2007-11-30 | 2011-02-24 | Foamix Ltd. | Foam containing benzoyl peroxide |
| US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
| US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
| US8343945B2 (en) | 2007-12-07 | 2013-01-01 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| US8709385B2 (en) | 2008-01-14 | 2014-04-29 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| US8491878B2 (en) | 2008-01-16 | 2013-07-23 | Glaxo Group Limited | Sanitizing formulation |
| WO2009090178A1 (en) * | 2008-01-16 | 2009-07-23 | Glaxo Group Limited | Novel formulation |
| US20090208444A1 (en) * | 2008-01-16 | 2009-08-20 | Simon King | Novel Formulation |
| CN101917842A (en) * | 2008-01-16 | 2010-12-15 | 葛兰素集团有限公司 | Novel formulations |
| US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
| US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
| US9072667B2 (en) | 2009-07-29 | 2015-07-07 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
| US8871184B2 (en) | 2009-10-02 | 2014-10-28 | Foamix Ltd. | Topical tetracycline compositions |
| US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US12138311B2 (en) | 2009-10-02 | 2024-11-12 | Journey Medical Corporation | Topical tetracycline compositions |
| US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US8618081B2 (en) | 2009-10-02 | 2013-12-31 | Foamix Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US8945516B2 (en) | 2009-10-02 | 2015-02-03 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US8865139B1 (en) | 2009-10-02 | 2014-10-21 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US8992896B2 (en) | 2009-10-02 | 2015-03-31 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10946101B2 (en) | 2009-10-02 | 2021-03-16 | Vyne Therapeutics Inc. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US10688117B2 (en) | 2011-05-27 | 2020-06-23 | Galderma S.A. | Topical wash composition for use in acne patients |
| RU2610172C2 (en) * | 2011-05-27 | 2017-02-08 | Галдерма С.А. | Composition for face washing |
| US10610594B2 (en) | 2012-11-13 | 2020-04-07 | Galderma S.A. | BPO wash gel composition |
| US11446272B2 (en) | 2012-11-13 | 2022-09-20 | Galderma Holding SA | BPO wash emulsion composition |
| US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3141821A (en) | Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis | |
| CA2084730C (en) | Skin antiseptic and hand disinfectant | |
| EP0077630B1 (en) | Topical antimicrobial compositions | |
| US6083517A (en) | Ultramild antibacterial cleaning composition for frequent use | |
| US5380756A (en) | Disinfecting shampoo composition for animals | |
| CA2107993C (en) | Disinfecting shampoo composition for animals | |
| US5767163A (en) | Lubricating and/or germicidal composition | |
| EP0086878B2 (en) | Mild antimicrobial detergent composition | |
| ATE132362T1 (en) | LIQUID DETERGENT COMPOSITION | |
| US4307089A (en) | Compositions of pyrithione metal salts and undecylenic acid alkylolamide derivatives | |
| US5492932A (en) | Lubrication germicidal composition | |
| JP2003502353A (en) | Antimicrobial composition | |
| US4252826A (en) | Cosmetic composition for removing makeup from the eyes | |
| US20060074029A1 (en) | Topical antimicrobial composition having improved moisturization properties | |
| Lilly et al. | Detergents compared with each other and with antiseptics as skin ‘degerming’agents | |
| US4184974A (en) | Liquid biocidal compositions comprising a mixture of silver ions and sodium pectate | |
| US4267168A (en) | Method of reducing bacteria on human tissue using liquid biocidal compositions comprising a mixture of silver ions and sodium pectate | |
| US4075353A (en) | Process for the treatment of acarid skin infections in animals | |
| AU668559B2 (en) | Improvements relating to cosmetic compositions | |
| US3886277A (en) | Methods of controlling dandruff using 5,7-dichloro-8-hydroxy quinoline | |
| WO1986005359A1 (en) | Antiseptic compositions | |
| US3629454A (en) | An antifungal and antibacterial composition | |
| US3671634A (en) | Stable aqueous anti-dandruff shampoo containing captan | |
| US3697655A (en) | Germicidal detergent compositions in controlling dandruff | |
| US2901399A (en) | Therapeutic preparations for topical application to the skin |